Business, energy, technology, markets and global industry news from Business News Today

Corcym

PharmaDeviceNews Corcym
Editorial infographic illustrating Corcym’s Perceval Plus aortic heart valve, featuring an anatomical heart, prosthetic valve and clinical imaging, with MANTRA study highlights showing 99.7% freedom from valve deterioration in extended follow-up and remaining durability questions.
Medical Devices & Diagnostics

A sutureless heart valve showed 99.7% freedom from deterioration. What do Corcym’s seven-year data really establish?

Corcym's Perceval Plus reports 99.7% freedom from valve deterioration in extended follow-up. Examine the MANTRA data and durability questions.

Read More
Medical Devices & Diagnostics

Corcym implants first TriMemo tricuspid ring. Can surgical repair keep pace with transcatheter therapy?

Cleveland Clinic has completed the first human implantation of Corcym’s TriMemo annuloplasty ring, moving a purpose-built Nitinol platform into tricuspid repair as cardiac surgery faces growing competition from transcatheter structural-heart therapies.

Read More